文献速递慢性肾脏病

碳酸氢钠两种剂量在CKD中的安全性、依从性和药效学比较:BASE试点试验

A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial.
PubMed 文献 · J Am Soc Nephrol · 2019-12-17

该多中心试点试验将194例eGFR 20-59 ml/min/1.73 m2、尿白蛋白/肌酐≥50 mg/g、血清碳酸氢盐20-28 meq/L的成人随机分为高剂量碳酸氢钠(0.8 meq/kg瘦体重/天)、低剂量(0.5 meq/kg瘦体重/天)或安慰剂组,治疗28周。两种剂量耐受性良好,不良事件和住院率与安慰剂相似;高剂量组血清碳酸氢盐更高、尿铵排泄更低,但ACR增加更明显。高剂量可能适合未来试验。

要点

  • 高剂量(0.8 meq/kg)和低剂量(0.5 meq/kg)碳酸氢钠在CKD患者中耐受性良好。
  • 高剂量组较低剂量组血清碳酸氢盐高1.3 meq/L,尿铵排泄低25%。
  • 高剂量组ACR增加30%,低剂量组增加12%,需关注白蛋白尿变化。

核心结论

  • 两种碳酸氢钠剂量在28周内耐受性良好,不良事件和住院率与安慰剂无显著差异。
  • 高剂量降低尿铵排泄并提高血清碳酸氢盐更明显,但与ACR增加更多相关。
  • 高剂量0.8 meq/kg瘦体重/天可能是未来试验的合理选择。

研究设计与样本

  • 多中心随机试点试验,纳入194例eGFR 20-44或45-59 ml/min/1.73 m2且尿ACR≥50 mg/g、血清碳酸氢盐20-28 meq/L的成人。
  • 随机分为高剂量碳酸氢钠(0.8 meq/kg瘦体重/天,n=90)、低剂量(0.5 meq/kg瘦体重/天,n=52)或安慰剂(n=52),治疗28周。
  • 主要结局为第28周处方剂量,剂量根据副作用调整。

主要发现

  • 基线平均eGFR 36±9 ml/min/1.73 m2,血清碳酸氢盐24±2 meq/L,中位ACR 181(IQR 25-745)mg/g。
  • 第28周全剂量比例:高剂量组87%,低剂量组96%,安慰剂组87%;≥25%方案剂量比例分别为91%、98%、92%。
  • 高剂量组较低剂量组平均尿铵排泄低25%,血清碳酸氢盐高1.3 meq/L。
  • 平均ACR在低剂量组增加12%,高剂量组增加30%。

临床怎么用

  • 在CKD伴正常血清碳酸氢盐且白蛋白尿患者中,碳酸氢钠0.8 meq/kg瘦体重/天耐受性良好,可考虑用于未来试验。
  • 使用高剂量碳酸氢钠时需监测白蛋白尿变化。

局限性

  • 试点试验样本量较小,主要结局为处方剂量而非临床硬终点。
  • 随访时间仅28周,长期安全性和疗效未评估。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Oral sodium bicarbonate (NaHCO3) may preserve kidney function in CKD, even if initiated when serum bicarbonate concentration is normal. Adequately powered trials testing this hypothesis have not been conducted, partly because the best dose for testing is unknown. METHODS: This multicenter pilot trial assessed the safety, tolerability, adherence, and pharmacodynamics of two doses of NaHCO3 over 28 weeks in adults with eGFR 20-44 or 45-59 ml/min per 1.73 m2 with urinary albumin/creatinine (ACR) ≥50 mg/g and serum bicarbonate 20-28 meq/L. We randomly assigned 194 participants from ten clinical sites to receive higher-dose (HD-NaHCO3; 0.8 meq/kg of lean body wt per day; n=90) or lower-dose (LD-NaHCO3; 0.5 meq/kg of lean body wt per day; n=52) NaHCO3 or matching placebo (n=52). The dose was adjusted depending on side effects. The prescribed dose at week 28 was the primary outcome; a dose was considered acceptable for a full-scale trial if ≥67% of participants were on full-dose and ≥80% were on ≥25% of the per-protocol dose. RESULTS: Mean±SD baseline eGFR was 36±9 ml/min per 1.73 m2, serum bicarbonate was 24±2 meq/L, and median (IQR) ACR was 181 (25-745) mg/g. Both doses were well tolerated without significant changes in BP, weight, or serum potassium. The proportions of adverse events and hospitalizations were similar across the groups. Consequently, 87% in HD-NaHCO3, 96% in LD-NaHCO3, and 87% in placebo were on full dose at week 28; and 91% in HD-NaHCO3, 98% in LD-NaHCO3, and 92% in placebo were on ≥25% of the per-protocol dose. Mean urinary ammonium excretion was 25% lower and serum bicarbonate concentration was 1.3 meq/L higher in HD-NaHCO3 compared with LD-NaHCO3 at week 28. However, mean ACR increased by 12% in the lower-dose group and 30% in the higher-dose group. CONCLUSIONS: Both NaHCO3 doses were well tolerated over 28 weeks with no significant difference in adverse events or hospitalization compared with placebo. The higher dose lowered urinary ammonium excretion and increased serum bicarbonate more than the lower dose but was associated with a greater increase in ACR. The higher 0.8 meq/kg of lean body wt per day dose of NaHCO3 may be a reasonable choice for future trials.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Raphael KL, Isakova T, Ix JH, et al. A Randomized Trial Comparing the Safety, Adherence, and Pharmacodynamics Profiles of Two Doses of Sodium Bicarbonate in CKD: the BASE Pilot Trial. J Am Soc Nephrol. 2019. PMID: 31848294. doi:10.1681/ASN.2019030287

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。